A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

NCT03605706 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: SHR-1210
DRUG: FOLFOX4
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.